ALX Oncology Holdings Inc. (NASDAQ:ALXO - Get Free Report) insider Jaume Pons sold 50,000 shares of the firm's stock in a transaction on Tuesday, April 16th. The shares were sold at an average price of $14.20, for a total value of $710,000.00. Following the sale, the insider now directly owns 604,205 shares of the company's stock, valued at $8,579,711. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.
Jaume Pons also recently made the following trade(s):
- On Thursday, April 4th, Jaume Pons sold 20,000 shares of ALX Oncology stock. The stock was sold at an average price of $11.15, for a total transaction of $223,000.00.
ALX Oncology Price Performance
ALX Oncology stock opened at $15.74 on Friday. The firm has a market capitalization of $789.36 million, a P/E ratio of -4.20 and a beta of 1.58. ALX Oncology Holdings Inc. has a one year low of $3.94 and a one year high of $17.42. The company has a debt-to-equity ratio of 0.05, a current ratio of 5.24 and a quick ratio of 5.24. The business has a fifty day moving average price of $13.55 and a 200-day moving average price of $11.90.
ALX Oncology (NASDAQ:ALXO - Get Free Report) last posted its earnings results on Thursday, March 7th. The company reported ($0.93) earnings per share for the quarter, missing analysts' consensus estimates of ($0.84) by ($0.09). As a group, equities research analysts forecast that ALX Oncology Holdings Inc. will post -3.33 EPS for the current year.
Analyst Ratings Changes
Truth about Trump you’ve never heard
From Porter & Company | Ad
Everything about Donald Trump is public.
Every part of his life has been dragged out in the media.
But there’s one story I bet you’ve never heard about Trump.
For the full story, click here.
A number of research firms recently commented on ALXO. Stifel Nicolaus reaffirmed a "hold" rating and issued a $14.00 price target (up previously from $10.00) on shares of ALX Oncology in a report on Friday, March 8th. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of ALX Oncology in a research note on Wednesday, April 10th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating on shares of ALX Oncology in a research report on Friday, April 12th. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $18.83.
View Our Latest Stock Report on ALXO
Hedge Funds Weigh In On ALX Oncology
Several hedge funds and other institutional investors have recently added to or reduced their stakes in ALXO. Legal & General Group Plc boosted its position in shares of ALX Oncology by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company's stock valued at $34,000 after acquiring an additional 684 shares during the last quarter. Credit Suisse AG increased its holdings in shares of ALX Oncology by 6.6% in the 2nd quarter. Credit Suisse AG now owns 15,157 shares of the company's stock worth $121,000 after buying an additional 940 shares during the last quarter. American International Group Inc. lifted its holdings in shares of ALX Oncology by 14.1% during the 2nd quarter. American International Group Inc. now owns 10,040 shares of the company's stock worth $81,000 after acquiring an additional 1,237 shares during the last quarter. Swiss National Bank grew its position in ALX Oncology by 8.5% in the first quarter. Swiss National Bank now owns 19,200 shares of the company's stock worth $324,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in ALX Oncology in the fourth quarter worth $28,000. 97.97% of the stock is currently owned by hedge funds and other institutional investors.
ALX Oncology Company Profile
(
Get Free Report)
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
